Safety issues of tofacitinib in rheumatoid arthritis patients: real-world pharmacovigilance
Enhanced monitoring is recommended for RA patients, especially those with comorbid malignancies, cardiovascular events, or infection risks, during tofacitinib therapy.
Authors
- Manting Liu (ORCID: https://orcid.org/0009-0004-7163-186X)
- Xiangyun Dou
- Shulan Huang
- Siyuan Zhou (ORCID: https://orcid.org/0000-0001-6092-4406)
- Yi Zeng (ORCID: https://orcid.org/0000-0002-5477-6686)
- Jiazhen Jiang
- Dongqiang Luo
- Jiayu Wu (ORCID: https://orcid.org/0009-0001-3288-8441)
- Bohui Zheng
Institutions
- Guangzhou University of Chinese Medicine (CN)
- The First People's Hospital of Shunde (CN)
- Integrated Chinese Medicine (China) (HK)
- Foshan Hospital of TCM (CN)
- Southern Medical University (CN)
Publication Details
- Journal
- Expert Opinion on Drug Safety
- Published
- 2025-06-30
- DOI
- https://doi.org/10.1080/14740338.2025.2527386
- Citations
- 3
- Primary Topic
- Rheumatoid Arthritis Research and Therapies
- Type
- article
- Field-Weighted Citation Impact
- 5.00